Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre Goy

Showing results (121-130 of 164) with videos related to

Pageof 17
Sort By:
Cancer|May 4, 2018
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphomaJorge E Romaguera, Michael Wang, Lei Feng, et al.
Journal of Hematology & Oncology|April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
Blood|June 11, 2015
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsMichael L Wang, Kristie A Blum, Peter Martin, et al.
Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Blood|March 10, 2019
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trialAndrew D Zelenetz, Gilles Salles, Kylie D Mason, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
Blood|January 15, 2016
Postibrutinib outcomes in patients with mantle cell lymphomaPeter Martin, Kami Maddocks, John P Leonard, et al.
Lancet (London, England)|December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
Genome Biology|June 30, 2020
Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPsCatherine Do, Emmanuel L P Dumont, Martha Salas, et al.
The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.
Pageof 17

Showing results (121-130 of 164) with videos related to

Sort By:
Pageof 17
Cancer|May 4, 2018
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphomaJorge E Romaguera, Michael Wang, Lei Feng, et al.
Journal of Hematology & Oncology|April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
Blood|June 11, 2015
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsMichael L Wang, Kristie A Blum, Peter Martin, et al.
Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Blood|March 10, 2019
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trialAndrew D Zelenetz, Gilles Salles, Kylie D Mason, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
Blood|January 15, 2016
Postibrutinib outcomes in patients with mantle cell lymphomaPeter Martin, Kami Maddocks, John P Leonard, et al.
Lancet (London, England)|December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
Genome Biology|June 30, 2020
Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPsCatherine Do, Emmanuel L P Dumont, Martha Salas, et al.
The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.
Pageof 17